LON:SCLP Scancell (SCLP) Share Price, News & Analysis GBX 13.60 -0.15 (-1.09%) As of 07/13/2026 12:37 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Scancell Stock (LON:SCLP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Scancell alerts:Sign Up Key Stats Today's Range 13.60▼ 14.5050-Day Range 13.60▼ 26.5052-Week Range 7.86▼ 29.50Volume482,676 shsAverage Volume1.96 million shsMarket Capitalization£141.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma. The precise patient population that iSCIB1+ brings benefit to, in combination with CPIs, has been identified, enabling precision-biomarker led registrational development. The lead Moditope® peptide active immunotherapy, Modi-1, is being investigated in a Phase 2 study in a broad range of solid tumours and also has shown encouraging interim clinical data. Scancell’s wholly-owned subsidiary, Glymab Therapeutics Ltd., has been established with the intention to develop an exciting early-stage pipeline of high affinity GlyMab® antibodies targeting tumour specific glycans, two of which already have been licensed and are being developed by Genmab A/S. Read More Receive SCLP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scancell and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SCLP Stock News HeadlinesScancell confirms advanced talks over reverse merger with NeuphoriaJune 26, 2026 | finance.yahoo.comScancell Holdings Plc: Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 studyApril 28, 2026 | finanznachrichten.deYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today. | Profits Run (Ad)Scancell's melanoma data keeps widening the gap over standard care as phase III funding race heats upApril 28, 2026 | finance.yahoo.comScancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 studyApril 28, 2026 | finance.yahoo.comScancell CFO to step down as cancer immunotherapy developer names interim replacementApril 2, 2026 | finance.yahoo.comScancell Holdings plc (LON:SCLP) has caught the attention of institutional investors who hold a sizeable 46% stakeJanuary 31, 2026 | finance.yahoo.comScancell Holdings Plc: Interim Results for the six months ended 31 October 2025January 29, 2026 | finanznachrichten.deSee More Headlines SCLP Stock Analysis - Frequently Asked Questions How have SCLP shares performed this year? Scancell's stock was trading at GBX 10.12 at the beginning of 2026. Since then, SCLP shares have increased by 34.4% and is now trading at GBX 13.60. How were Scancell's earnings last quarter? Scancell Holdings plc (LON:SCLP) released its earnings results on Thursday, January, 29th. The company reported ($0.55) earnings per share for the quarter. Scancell had a negative net margin of 116.98% and a positive trailing twelve-month return on equity of 90.29%. How do I buy shares of Scancell? Shares of SCLP stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Scancell own? Based on aggregate information from My MarketBeat watchlists, some other companies that Scancell investors own include KAZ Minerals (KAZ), Petropavlovsk (POG), Standard Chartered (STAN), AorTech International (AOR), Ascential (ASCL), Advanced Oncotherapy (AVO) and Empyrean Energy (EME). Company Calendar Last Earnings1/29/2026Today7/14/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:SCLP CIKN/A Webwww.scancell.co.uk Phone+44-115-8231863FaxN/AEmployees51Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£6.75 million Net Margins-116.98% Pretax MarginN/A Return on Equity90.29% Return on Assets-45.28% Debt Debt-to-Equity Ratio-193.29 Current Ratio0.56 Quick Ratio13.01 Sales & Book Value Annual Sales£4.71 million Price / Sales29.96 Cash FlowGBX 1.73 per share Price / Cash Flow7.86 Book ValueGBX (0.39) per share Price / Book-34.89Miscellaneous Outstanding Shares1,037,781,000Free FloatN/AMarket Cap£141.14 million OptionableNot Optionable Beta0.74 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (LON:SCLP) was last updated on 7/14/2026 by MarketBeat.com Staff. From Our PartnersSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThey told you not to miss this oneThe largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...Thor Metals | SponsoredForget SpaceX, this is Elon’s Next BreakthroughJeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI pa...Brownstone Research | SponsoredWhen I found Rolls-Royce under $2, most people thought I was crazyIn 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...Monument Traders Alliance | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scancell Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Scancell With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
